Vanguard Asset Management’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.13M Sell
87,077
-3,281
-4% -$91.3K ﹤0.01% 1525
2026
Q2
$3.1M Buy
90,358
+9,661
+12% +$292K ﹤0.01% 1336
2026
Q1
$1.92M Buy
+80,697
New +$2.24M ﹤0.01% 1490

Other funds holding BEAM

Vanguard Asset Management's BEAM Position: Q3 2026 in Review

Vanguard Asset Management reduced its Beam Therapeutics (BEAM) stake by 3.6% in Q3 2026, selling an estimated $91.3K and leaving 87,077 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1525.

Vanguard Asset Management first reported a position in BEAM in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.1M in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Vanguard Asset Management held 87,077 shares of Beam Therapeutics worth $2.13M as of Q3 2026.
  • Vanguard Asset Management sold 3,281 Beam Therapeutics shares in Q3 2026, an estimated $91.3K.
  • Beam Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1525 holding.
  • Vanguard Asset Management first reported a position in Beam Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's Beam Therapeutics position peaked at $3.1M in Q2 2026.
  • 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.